Ibex Medical Analytics Accelerates Global Momentum in AI-Powered Pathology with Strategic Leadership Transition and Expansion in Biopharma
Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced continued commercial momentum and expanding global adoption alongside a leadership transition designed to accelerate the company’s next phase of growth. Effective immediately, Yair Heller, formerly Chief Operating Officer, has been appointed Chief Executive Officer, and co-founder Joseph Mossel will lead Ibex’s rapidly expanding biopharma division and U.S. clinical growth initiatives.
“Ibex has been built on a strong foundation and is entering 2026 with tremendous momentum and a clear path to scaling our platform globally,” said Yair Heller, Ibex’s Chief Executive Officer. “As we scale, we will continue delivering the most accurate and reliable tools for pathologists to help improve patient care, while also leveraging our platform to accelerate drug development pipelines and improve evidence quality worldwide.”
The company is celebrating a series of significant commercial milestones, including strategically important clinical deployments with two of the largest laboratory networks in Europe, as well as PathGroup and HNL Lab Medicine in the U.S., as well as significant expansions from existing customers such as Fimlab in Finland. These partnerships underscore the global shift toward AI-powered pathology as the gold standard for cancer detection.